CLINICAL APPLICATIONS OF PACLITAXEL IN CANCER THERAPY
DOI:
https://doi.org/10.56782/pps.10Keywords:
paclitaxel, breast cancer, non-small cell lung cancer, immunotherapy, nab-paclitaxelAbstract
Paclitaxel (PTX) is a natural anti-cancer drug – a terpene alkaloid from the taxane group, used in the treatment of non-small cell lung carcinoma, ovarian and breast cancer as well Kaposi’s sarcoma. PTX shows a very good therapeutic effect when is used in monotherapy and in combination with other anti-cancer drugs. For the first time, it was isolated from the Pacific yew bark (Taxus brevifolia) and introduced into treatment under the name “Taxol” by the American biopharmaceutical company Bristol-Myers Squibb. The basic mechanism of its action consists in blocking the cell cycle during the G2/M phase by blocking depolymerization of microtubules, which inhibits mitosis. Moreover, PTX can cause cell necrosis through multipolar divisions and incorrect chromosome segregation.
Downloads
References
Kordek R.: Onkologia. Podręcznik dla studentów i lekarzy, Wyd. 2, Gdańsk: Via Medica, 2006, 320-322.
Krajowy Rejestr Nowotworów, Zakład Epidemiologii i Prewencji Nowotworów Centrum Onkologii, wzięto z http://onkologia.org.pl/ z dnia 25.03.2020.
Stachura J., Domagała W.: Patologia: znaczy słowo o chorobie. Tom 1, Patologia ogólna, Kraków, PAU, 2008, 35-40.
Mitrus I., Szala S.: Chemioterapia – główne przyczyny niepowodzeń, Nowotwory, Journal of Oncology, 2009, 368-375.
Kuszyk B., Corl F., Franano F.: Tumor transport physiology: implications for imaging and imaging-guided therapy, Am J Roentgenol, 2001, 177(4): 747-753. DOI: https://doi.org/10.2214/ajr.177.4.1770747
Cairns R., Papandreou I., Denko N.: Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment, Molecular Cancer Research, 2006, 4(2): 61-70. DOI: https://doi.org/10.1158/1541-7786.MCR-06-0002
Minchinton A.I., Tannock I.F.: Drug penetration in solid tumours, Nature Reviews Cancer, 2006, 6(8): 583-592. DOI: https://doi.org/10.1038/nrc1893
Blagosklonny M.V.: Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance, Cell Cycle, 2005, 4(2): 1693-1698. DOI: https://doi.org/10.4161/cc.4.12.2259
Huff C.A., Matsui W., Smith B.D.: The paradox of response and survival in cancer therapeutics. Blood, 2006, 107(2): 431-434. DOI: https://doi.org/10.1182/blood-2005-06-2517
Janik P.: Stemowe komórki nowotworowe, Nowotwory. Journal of Oncology, 2008, 58(3): 221-224.
Grzelakowska-Sztabert B.: Post Biochem, Folia Morphology, 1989, 35(2): 513-541.
Wang L.G., Liu X.M., Kreis W., Budman D.: Cancer Chemotherapy, Pharmacol, 1999, 44(2): 355-361. DOI: https://doi.org/10.1007/s002800050989
Krishan A.: Med Cell Science, Journal of Cell Science, 2002, 24(2): 55-60. DOI: https://doi.org/10.1023/A:1015513705359
Orzechowska-Juzwenko K.: Zarys chemioterapii nowotworów narządowych i układowych, Volumed, Wrocław, 2000, 13-73.
Nowak R., Tarasiuk J.: Hamowanie procesu apoptozy w komórkach nowotworowych opornych na działanie leków przeciwnowotworowych, 2004, 4(4): 330-343.
Li T.K,, Liu L.F. Toxicol,, Annual Reviev of Pharmacology, 2001, 41(2): 53-77. DOI: https://doi.org/10.1146/annurev.pharmtox.41.1.53
Bozko P., Larsen K., Raymond E., Skladanowski A.: Influence of G arrest on the cytotoxicity of DNA topoisomerase inhibitors toward human carcinoma cells with different p53 status, Acta Biochimica Polonica, 2002, 49(1): 109-119. DOI: https://doi.org/10.18388/abp.2002_3827
Krawczyk P., Kucharczyk T., Limon J., Dziadziuszko R., Milanowski J., Jassem J.: Prawne i metodologiczne aspekty genetycznych testów diagnostycznych w kwalifikacji chorych na nowotwory do terapii ukierunkowanych molekularnie, Journal of Oncology, 2013, 63(1): 1-7.
Pruszyński M.: Projektowanie, otrzymywanie i charakterystyka nowych radiofarmaceutyków molekularnych do diagnostyki i terapii nowotworów z nadekspresją receptora HER2, Instytut Chemii i Techniki Jądrowej, 2018.
Wysocki P.: Mechanizmy działania przeciwciał monoklonalnych w nowotworach litych, Onkologia w Praktyce Klinicznej, 2014, 10: 175- 183.
Krawczyk P., Wojas-Krawczyk K.: Przeciwciała monoklonalne przeciw immunologicznym punktom kontroli w leczeniu chorych na nowotwory, Onkologia w Praktyce Klinicznej, 2015,11(2): 76-86.
Postow M.A., Callahan M.K., Wolchok J.D.: Immune checkpoint blockade in cancer therapy. J. Clinical Oncology 2015; 20: 4358. DOI: https://doi.org/10.1200/JCO.2014.59.4358
Gurgul A., Lityńska A.: Substancje pochodzenia roślinnego w terapii nowotworów, Post Fitoter 2017, 18(1): 203-208. DOI: https://doi.org/10.25121/PF.2017.18.3.203
Rowinsky E.K., Cazenave L.A., Donehower R.: Taxol: a novel investigation alantimicrotubule agent, Journal of the National Cancer Institute, 1990, 82(15): 1247-59. DOI: https://doi.org/10.1093/jnci/82.15.1247
Bodnar L., Wcisło G., Miedzińska-Maciejewska M., Szczylik C.: Docetaksel i paklitaksel: porównanie ich budowy, farmakologii oraz mechanizmów oporności, Postepy Higieny i Medycyny Doświadczalnej, 2010, 64(2): 568-581.
O’Brien M.E.R., Leonard R.C., Barrett-Lee P.J.: Docetaxel in the community setting: An analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK., Oncology 1999, 10(6): 205-210. DOI: https://doi.org/10.1023/A:1008370930599
Huisman C., Smit E.F., Giaccone G, Postmus P.E.: Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer, Journal of Clinical Oncology, 2000, 18(4): 3722-3730. DOI: https://doi.org/10.1200/JCO.2000.18.21.3722
Forastiere A., Shank D., Neuberg D.: Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck, Cancer 1998, 82(1): 22-70. DOI: https://doi.org/10.1002/(SICI)1097-0142(19980601)82:11<2270::AID-CNCR24>3.0.CO;2-Q
Conteau C., Chouaki N., Leyvraz S.: Phase II study of docetaxel in patients with metastatic squamous cellcarcinoma of the head and neck, British Journal of Cancer,1999, 81(1): 457-462. DOI: https://doi.org/10.1038/sj.bjc.6690715
Charakterystyka produktu leczniczego Paclitaxel, styczeń, 2017.
Khazir J., Mir B.A., Pilcher L.: Role of plants in anticancer drug discovery, Phytochemistry Letters, 2014, 7(4):173-181. DOI: https://doi.org/10.1016/j.phytol.2013.11.010
Kampan N., Madondo M., McNally O.: Paclitaxel and its evolving role in the management of ovarian cancer, Biomed Research International, 2015,1-21. DOI: https://doi.org/10.1155/2015/413076
Kingston D., Mangri N., Jintrangsri C.: Synthesis and structureactivity relationships of taxol derivatives as anti-cancer agents, New Trends in Natural Products Chemistry, 1986, 26(1): 219-234.
Lowe J., Li H. Downing, K. Nogales J.: Refined structure of alpha;beta;-tubulin at 3.5 p resolution, Journal of Molecular Biology, 2001, 31(3): 1045-1057. DOI: https://doi.org/10.1006/jmbi.2001.5077
Bharadwaj K., Rajnish D., Yu H., Hongtao R.: The spindle checkpoint, aneuploidy and cancer, Oncogene, 2004, 23(12): 2016-2027. DOI: https://doi.org/10.1038/sj.onc.1207374
Brito D. A., Yang, Z., Rieder, C. L.: Microtubules do not promote mitotic slippage when the spindle assembly checkpoint cannot be satisfied, The Journal of Cell Biology, 2004, 182(4): 623-629. DOI: https://doi.org/10.1083/jcb.200805072
Weaver B.A.: How taxol/paclitaxel kills cancer cells, Molecular Biology of the Cell, 2014; 25(6): 2677-8. DOI: https://doi.org/10.1091/mbc.e14-04-0916
Szoka Ł.: Metody biotechnologiczne w otrzymywaniu taksolu – cytostatycznego diterpenu cisów (Taxus), Gazeta Farmaceutyczna, 2009, 18(9):34-36.
Goodman J., Walsh V.: The Story of Taxol: Nature and Politics in the Pursuit of an Anti-Cancer Drug, Cambridge University, 2001,179-182.
Stierle A., Strobel G., Stierle D.: Taxol and taxane production by Taxomyces andreanae, an endophytic fungus of pacific yew. Science, 1993, 260(11): 214-216. DOI: https://doi.org/10.1126/science.8097061
Linyan Z., Chen L.: Progress in research on paclitaxel and tumor immunotherapy, Cellular and Molecular Biology Letters, 2019, 24-40.
Liu K., Ding X., Deng B., Chen W.: Isolation and characterization of endophytic taxol-producing fungi from Taxus chinensis, Journal of Industral Microbiology and Biotechnology, 2009, 36(5): 1171-1177. DOI: https://doi.org/10.1007/s10295-009-0598-8
Heinig U., Scholz S., Jennewein S.: Getting to the bottom of Taxol biosynthesis by fungi, Fungal Divers, 2013, 60(1): 161-170. DOI: https://doi.org/10.1007/s13225-013-0228-7
Kusari S., Singh S., Jayabaskaran C.: Rethinking production of Taxol; (paclitaxel) using endophyte biotechnology, Trends Biotechnol, 2014, 32(7): 304-311. DOI: https://doi.org/10.1016/j.tibtech.2014.03.011
Zhou X.W., Zhu H.F., Liu L., Lin J., Tang K.X.: A review: recent advances and future prospects of taxol-producing endophytic fungi, Applied Microbiology and Biotechnology, 2010, 86(3): 1707-1017. DOI: https://doi.org/10.1007/s00253-010-2546-y
Yang Y., Mao J., Tan X.: Research progress on the source, production, and anti-cancer mechanisms of paclitaxel, Chinese Journal of Natural Medicines, 2020, 18(12): 890-897. DOI: https://doi.org/10.1016/S1875-5364(20)60032-2
Rowinsky E.K., Wright M., Montsarrat B., Done-Hower R.C.: Clinical pharmacology and metabolism of Taxol (paclitaxel), Annals of Oncology, 1994, 5(1): 7-16.
Charakterystyka produktu leczniczego Paclitaxel Kabi, Fresenius Kabi Polska Sp. z.o.o., styczeń, 2020.
Charakterystyka produktu leczniczego Paclitaxelum Accord Accord Healthcare Polska Sp. z o.o., listopad, 2012.
Charakterystyka produktu leczniczego Paclimedac medac Gesellschaft für klinische Spezialpräparate mbH, lipiec, 2015.
Charakterystyka produktu leczniczego Paclitaxel-Ebewe Ebewe Pharma Ges.m.b.H Nfg. KG, listopad, 2019.
Adrianzen D. Herrera, Ashai N., Perez-Soler R., Cheng H.: Nanoparticle albumin bound paclitaxel for treatment of advanced non-small cell lung cancer: an evaluation of the clinical evidence, Expert Opinion on Pharmacotherapy, 2019, 1: 95-102. DOI: https://doi.org/10.1080/14656566.2018.1546290
Torre L.A., Siegel R.L., Jemal A.: Lung cancer statistics, Advances in Experimental Medicine and Biology, 2016, 893(1): 1-19. DOI: https://doi.org/10.1007/978-3-319-24223-1_1
Gelderblom H., Verweij J., Nooter K.: Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation, European Journal of Cancer, 2001, 37(1): 1590-1598. DOI: https://doi.org/10.1016/S0959-8049(01)00171-X
Socinski M.A., Bondarenko I., Karaseva N.: Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced nonsmall-cell lung cancer: final results of a phase III trial, Journal of Clinical Oncology, 2012, 30(1): 2055-2062. DOI: https://doi.org/10.1200/JCO.2011.39.5848
Ibrahim N.K., Desai N., Legha S.: Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel, Clinical Cancer Research, 2002, 5(3): 1038-1044.
Szebeni J. , Alving C.R., Savay S.: Formation of complementactivating particles in aqueous solutions of Taxol: possible role in
hypersensitivity reactions, Internationa Immunopharmacolpgy, 2001, 4(2): 721-735.
Gardner E.R., Dahut W.L., Scripture C.D.: Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nabpaclitaxel, Clinical Cancer Research, 2008, 14(2): 4200–4205. DOI: https://doi.org/10.1158/1078-0432.CCR-07-4592
Tiruppathi C., Song W., Bergenfeldt M.: Gp60 activation mediates albumin transcytosis in endothelial cells by tyrosine kinasedependent pathway, Journal of Biological Chemistry, 1997, 272(2): 259-265. DOI: https://doi.org/10.1074/jbc.272.41.25968
Prakash V., Vivek R.: Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer, Breast Cancer: Basic and Clinical Research, 2011:5 53-65. DOI: https://doi.org/10.4137/BCBCR.S5857
Tala M., Samaan A., Samec M., Liskova A., Kubatka P., Büsselberg D.: Paclitaxel’s Mechanistic and Clinical Effects on Breast Cancer, Biomolecules, 2019, 9(2): 788-789. DOI: https://doi.org/10.3390/biom9120789
Ferlay K., Colombet J., Soerjomataram M., Mathers J., Parkin C., Piñeros D., Znaor M., Bray A.: Estimating the global cancer incidence
and mortality, Globocan, sources and methods, International Journal of Cancer, 2019, 144(4): 1941-1953. DOI: https://doi.org/10.1002/ijc.31937
McPherson K., Steel C., Dixon M.: Breast cancer—Epidemiology, risk factors and genetics, British Medical Journal, 2000, 321(2): 624-628. DOI: https://doi.org/10.1136/bmj.321.7261.624
Amin B.A., Edge S.B.: Cancer staging manual, Springer, New York, 2017, 93-99. DOI: https://doi.org/10.3322/caac.21388
Jassem J., Krzakowski M., Bobek-Billewicz B., Duchnowska R., Jeziorski A., Olszewski W., Senkus-Konefka E., Tchórzewska-Korba H., Wysocki P.: Rak piersi, Onkologia w Praktyce Klinicznej, 2015, 11(3): 24-52.
Yu, D. Jing, T. Liu, B. Yao, J. Tan, M. McDonnell, T.J. Hung, M.: Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase, Molecular Cell, 1998, 2(3): 581-591. DOI: https://doi.org/10.1016/S1097-2765(00)80157-4
Hayes D.F. Thor, A.D., Dressler L.G., Weaver D., Edgerton S., Cowan D., Broadwater, G. Goldstein, L.J. Martino, S. Ingle, J.: HER2 and response to paclitaxel in node-positive breast cancer, The New England Journal of Medicine, 2007, 357(2): 1496-1506. DOI: https://doi.org/10.1056/NEJMoa071167
Pogoda K., Krzakowski M., Jagiełło-Gruszfeld A.: Metronomic chemotherapy in breast cancer. Oncology in Clinical Practice, 2017;13:161-168.
Cancello G, Bagnardi V, Sangalli C:Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast Cancer, Clinical Breast Cancer, 2015, 15(4): 259-265 DOI: https://doi.org/10.1016/j.clbc.2015.03.002
Green M.R., Manikhas G.M., Orlov S.: Abraxane, a novel Cremophorfree, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer, Annal of Oncology, 2006, 8(11): 1263-1268. DOI: https://doi.org/10.1093/annonc/mdl104
Rizvi N.A., Riely G.J., Azzoli C.G.: Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer, Journal of Clinical Oncology, 2008, 26(1): 639-643. DOI: https://doi.org/10.1200/JCO.2007.10.8605
Urbański K.: Terapia konsolidacyjna chorych na raka jajnika. Argumenty za i przeciw, Onkologia w Praktyce Klinicznej, 2007 Tom 3, nr 6, 298-305.
Jiying Y., Zengjuan J., Shufang D.: Cisplatin and paclitaxel codelivered by folatedecorated lipid carriers for the treatment of head and neck cancer, Drug Delivery, 2017, 24(1): 792-799. DOI: https://doi.org/10.1080/10717544.2016.1236849
Roszkiewicz J., Nedoszytko B., Lange M.: Mięsak Kaposiego — fascynująca historia współczesnej medycyny, Forum Medycyny Rodzinnej 2010, 4(4): 246-254.
Kim S., Kim D., Lee H., Young J., Lee J., M.D.: Treatment of Disseminated Classic Type of Kaposi’s Sarcoma with Paclitaxel, Annals of Dermatology, 2011, 23(4):504-7. DOI: https://doi.org/10.5021/ad.2011.23.4.504
Bower M., Palfreeman A., Alfa-Wali M., Bunker C.: British HIV Association guidelines for HIV-associated malignancies, HIV Medicine, 2014, 15(2): 1-92. DOI: https://doi.org/10.1111/hiv.12136
Zhu L., Chen L.: Progress in research on paclitaxel and tumor immunotherapy, Cellular and Molecular Biology Letters, 2019, 12: 24-40. DOI: https://doi.org/10.1186/s11658-019-0164-y
Mackiewicz J., Mackiewicz A.: Immunoterapia nowotworów i perspektywy jej rozwoju, Współczesna Onkologia, 2010, 14(2): 59-71. DOI: https://doi.org/10.5114/wo.2010.13914
Vassileva V., Allen C.J., Piquette-Miller M.: Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer, Molecular Cancer Therapy, 2008, 7(3): 630-637. DOI: https://doi.org/10.1158/1535-7163.MCT-07-2117
Lesterhuis W.J., Cornelis J.A.P., Hato S.V., Dagmar E.T., Bastiaan J.H.J., Stefan N.: Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice, Journal of Clinical Investigation, 2011, 12(1): 8-31
Spigel D.R., Patel J.D., Reynolds C.H., Garon E..B, Hermann R.C., Govindan R.: Quality of life analyses from the randomized, openlabel, phase III PointBreak study of pemetrexed-carboplatinbevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin -bevacizumab followed by maintenance bevacizumab in patients, Journal of Thoracic Oncology, 2015, 10(4): 353-359. DOI: https://doi.org/10.1097/JTO.0000000000000277
Nagańska E.: Powikłania neurologiczne po leczeniu onkologicznym, Przewodnik Lekarza 2010, 9: 54-59.
Drat-Gzubicka J.: Schorzenia nerwowo-mięśniowe u pacjentów z chorobą nowotworową, Medycyna Paliatywna w Praktyce, 2015, 9(1): 8-15.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Prospects in Pharmaceutical Sciences copyright is retained by the authors. The journal publishes articles in the Open Access policy, within the CC BY 4.0 licence.
This is a human-readable summary of (and not a substitute for) the license. Disclaimer.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
How to Cite
